Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 3/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.76 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.58 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.58 |
| ▸ | PDE1A | P54750 | 2/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.41 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.41 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17805815 | 0.91 | BCL2L1 (0.84) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL19425571 | 0.91 | BCL2L1 (0.83) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL4651385 | 0.89 | BCL2L1 (0.98) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL4652392 | 0.88 | BCL2L1 (0.79) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL4652386 | 0.88 | BCL2L1 (0.79) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL4651590 | 0.87 | TP53 (1.00) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL19420098 | 0.86 | BCL2L1 (0.75) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL4652550 | 0.86 | BCL2L1 (0.75) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL5559504 | 0.86 | BCL2L1 (0.74) | BCL2L1MCL1TP53MDM2BCL2L11 | |
| SCHEMBL14347691 | 0.83 | BCL2L1 (0.71) | BCL2L1MCL1TP53MDM2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161851-A1 | COMBINATION THERAPY OF LYMPHOMA | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2021-06-03 | — | — | US | disclosed |
| US-20180161391-A1 | INHIBITORS OF BCL-2 | UNIV CASE WESTERN RESERVE (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170224678-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| US-20170224678-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| US-9657073-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657073-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160158189-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-08-22 | — | — | US | disclosed |
| US-8445441-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110312896-A1 | INHIBITORS OF BCL-2 | DISTELHORST CLARK W (US) | 2011-12-22 | — | — | US | disclosed |
| US-8034779-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034779-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| EP-1408986-B1 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050215563-A1 | Proteomimetic compounds and methods | YALE UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-6858600-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | BCL2L1 716/4885MCL1 1291/4885TP53 468/4885 |
| US-20170224678-A1 | INHIBITORS OF BCL-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885MCL1 14/4885TP53 44/4885 |
| US-20210161851-A1 | COMBINATION THERAPY OF LYMPHOMA | IKBKB, NFKBIA, BCL3 | BCL2L1 23/4885MCL1 21/4885TP53 102/4885 |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | BCL2L1 3/4885MCL1 16/4885TP53 179/4885 |
| US-20180161391-A1 | INHIBITORS OF BCL-2 | BCLAF1, BCL2L1, BCL2L11 | BCL2L1 2/4885MCL1 13/4885TP53 74/4885 |
| US-20110312896-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | BCL2L1 3/4885MCL1 16/4885TP53 179/4885 |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | BCLAF1, BCL2L1, BCL2L11 | BCL2L1 2/4885MCL1 13/4885TP53 74/4885 |
| US-20160158189-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | CASP5, API5, BAX | BCL2L1 28/4885MCL1 10/4885TP53 68/4885 |
| US-20050215563-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | BCL2L1 716/4885MCL1 1291/4885TP53 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.